Covetrus Inc (CVET) Stock Analyst Ratings
NASDAQ:CVET - Nasdaq - US22304C1009 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 51% to CVET. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 21.76. This target is 3.67% above the current price.
CVET was analyzed by 11 analysts. The buy percentage consensus is at 51. So analysts seem to be rather neutral about CVET.
In the previous month the buy percentage consensus was at a similar level.
CVET was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-06-13 | Stifel | Downgrade | Buy -> Hold |
| 2022-05-26 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2022-05-25 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-05-23 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2022-05-23 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-05-19 | Goldman Sachs | Maintains | Sell |
| 2022-05-09 | Barclays | Maintains | Overweight |
| 2022-05-06 | Raymond James | Maintains | Outperform |
| 2021-11-18 | Morgan Stanley | Initiate | Equal-Weight |
| 2021-11-05 | Raymond James | Maintains | Outperform |
| 2021-08-09 | Barclays | Maintains | Overweight |
| 2021-08-06 | Raymond James | Maintains | Outperform |
| 2021-07-12 | Guggenheim | Upgrade | Neutral -> Buy |
| 2021-03-02 | Raymond James | Maintains | Outperform |
| 2021-02-17 | Barclays | Initiate | Overweight |